Opinion

Video

Fixed-Duration Options for CLL

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite therapy.

Content above is prompted by the following:

  • A key distinction between preferred upfront therapies for CLL—venetoclax-based regimens and Bruton tyrosine kinase (BTKi)–based regimens—is that venetoclax offers a fixed-duration option, while BTKi therapy is typically continuous. However, studies presented at the 2024 American Society of Hematology annual meeting explored the efficacy and safety of fixed-duration BTKi therapy in the first-line setting. How might adopting fixed-duration BTKi therapy influence treatment choices in the relapsed/refractory CLL setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Miriam Freimer, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo